Factors Associated with Neurotoxicity in Patients Receiving FOLFOX 4

DOI 2 Citations 11 References

Bibliographic Information

Other Title
  • FOLFOX 4 療法における末梢神経障害発症に関与する臨床的因子の検討

Search this article

Abstract

Oxaliplatin (L-OHP) in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) has been established as a core therapy for advanced and recurrent colorectal cancer.In this case,sensory neurotoxicity is its dose-limiting toxicity.We evaluated it using the Neurotoxicity Criteria of DEBIOPHARM and conducted a retrospective analysis to determine sensory neurotoxicity-associated clinical factors.<br>Seventy patients with advanced recurrent colorectal cancer who received FOLFOX 4 therapy from November 2005 to February 2008 were the subjects of the present study.The median number of courses until expression of grade 1 neurotoxicity was six (range 1~17 courses) and that for grade 2 neurotoxicity was ten (range 3~18 courses).<br>A logistic regression analysis performed to determine patient background and laboratory data that affect the incidence of sensory neurotoxicity revealed that risk factors involving sensory neurotoxicity were WBC(×~103/μL)[odds ration: 0.7556 (95% confidence interval:0.6740-0.8471)],Amylase (Logarithm natural)[1.7766:(1.0879-2.9011)],Transition [1.7850:(1.1647-2.7354)]and L-OHP cumulative dose (g)[2.2399:(1.5810-3.1734)].<br>These findings suggest that pharmacists should carefully monitor the rational symptoms in patients undergoing FOLFOX for advanced and recurrent colorectal cancer,particularly in those with risk factors for sensory neurotoxicity.

Journal

Citations (2)*help

See more

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top